Serum levels of interleukin 33 and its receptor ST2 in patients treated with subcutaneous allergen immunotherapy in intermittent allergic rhinitis

AbstractData regarding clinical relevance of house dust mite (HDM) components over allergen immunotherapy (AIT) for allergic rhinitis (AR) are lacking. 18 adult AR patients receiving HDM-AIT for 52 weeks were followed up to assess serum levels of sIgE and sIgG4 to HDM components. The study showed that Der p1, p2, p23, Der f1 and f2, are important sensitizing components of HDM, of which Der p1 appears to be the most clinically relevant allergenic component for effective AIT.

Download Full-text

Elevated Serum Level of CD48 in Patients with Intermittent Allergic Rhinitis

International Archives of Allergy and Immunology ◽

10.1159/000510166 ◽

2020 ◽

Vol 182 (1) ◽

pp. 39-48

Author(s):

Olga Branicka ◽

Edyta Jura-Szołtys ◽

Barbara Rogala ◽

Joanna Glück

Keyword(s):

Allergic Rhinitis ◽

Mast Cell ◽

Serum Level ◽

Pollen Season ◽

Complete Blood Count ◽

Elevated Serum ◽

Serum Levels ◽

Nasal Symptom ◽

Soluble Form ◽

Intermittent Allergic Rhinitis

Background: In the pathogenesis of intermittent allergic rhinitis (IAR), the inflammatory reaction is of importance. CD48, belonging to the CD2 family, participates in mast cell-stimulating cross-talk, facilitates the formation of the mast cell/eosinophil effector unit, and is expressed by eosinophils. Objectives: To assess the serum level of soluble form of CD48 (sCD48) in patients with IAR during and out of the pollen season and correlate with the disease severity and with eosinophil-related parameters. Materials and Methods: Sixty-three patients (female: 79%; mean age: 30.58) were included to the study. Forty-five patients were assessed during the pollen season and other 42 patients during out of the pollen season. Twenty-four patients (female: 37.50%; mean age: 27.90) were evaluated twice, during the pollen season and out of the pollen season. sCD48, ECP, eotaxin-1/CCL11 serum levels together with complete blood count, and fractional exhaled nitric oxide bronchial and nasal fraction (FeNO) were performed. The severity of symptoms was assessed using the Total Nasal Symptom Score (TNSS), and neutrophil-to-lymphocyte (NLR) and eosinophil-to-lymphocyte (ELR) ratios were calculated. Results: sCD48 serum level, FeNO nasal and bronchial fractions, and TNSS were significantly higher in the IAR group in the pollen season compared with out of the pollen season. Differences in ECP, eotaxin-1/CCL11 serum levels, and NLR and ELR were not significant between season and out of the season. No correlations were found between sCD48 and eosinophil-related parameters. Conclusions: sCD48 may be a biomarker to the exacerbation phase in patients with IAR. One can assume that CD48 participates in the pathogenesis of IAR.

Download Full-text

On the Relationship Between Serum Level of Interleukin-33 with Allergic Rhinitis and Its Severity in Children

Iranian Journal of Pediatrics ◽

10.5812/ijp.105094 ◽

2021 ◽

Vol In Press (In Press) ◽

Author(s):

Marzieh Heidarzadeh Arani ◽

Sara Nikafarin ◽

Hamidreza Gilasi

Keyword(s):

Allergic Rhinitis ◽

Serum Level ◽

Serum Levels ◽

Study Data ◽

High Serum ◽

Th2 Cells ◽

Control Group ◽

Case Group ◽

Interleukin 33 ◽

Pediatric Clinic

Background: T helper type 2 (Th2) cells are critical cellular elements in allergic rhinitis. Interleukin-33 (IL-33) produces Th2-related cytokines and binds to the ST2 receptors. This is expressed strongly in mastocytes and discerningly in Th2 cells. Through Th2 cells, IL-33 may also have partly involved in immune responses. Objectives: This study aimed to measure the IL-33 serum levels in children suffering from allergic rhinitis and investigate its relationship with the disease. Methods: This case-control study was conducted on a population with the age range of 7-18 years, who referred to the Pediatric Clinic of the Shahid Beheshti Hospital in Kashan, Iran, in 2017. The study sample encompassed 57 patients with allergic rhinitis (case group) and 57 subjects with no allergic rhinitis (control group). The ELISA assay was used to measure the serum level of IL-33 in the case and control groups. Allergic rhinitis was diagnosed by a pediatric immunologist considering the patient’s history and the guidelines set out by the Allergic Rhinitis and its Impact on Asthma (ARIA). All study data were analyzed with SPSS software version 22. Results: There were significant differences between the two groups in terms of age (P = 0.001), gender (P = 0.0144), family history of atopy (P < 0.001), symptoms duration (P < 0.001), and comorbidities (e.g., atopic dermatitis and asthma) (P < 0.001). Furthermore, compared to the control group, the case group exhibited significantly higher IL-33 serum levels (P < 0.001). Conclusions: The high serum levels of IL-33 exhibited in patients with allergic rhinitis indicate its involvement in the pathogenesis of the concerned disease.

Download Full-text

Comparison of serum interleukin-33 levels in children with allergic respiratory diseases

Medicinski pregled ◽

10.2298/mpns2004088m ◽

2020 ◽

Vol 73 (3-4) ◽

pp. 88-93

Author(s):

Borko Milanovic ◽

Gordana Vijatov-Djuric ◽

Mirjana Stojsic ◽

Aleksandra Milutinovic ◽

Jelena Stojcevic-Maletic

Keyword(s):

Allergic Rhinitis ◽

Allergic Asthma ◽

Respiratory Diseases ◽

Serum Levels ◽

Asthma Severity ◽

Control Group ◽

Healthy Children ◽

Interleukin 33 ◽

Relationship Of ◽

The Relationship

Introduction. Recent studies point to the importance of interleukin-33 in the pathogenesis of allergic respiratory diseases. The relationship of interleukin-33 and certain allergic respiratory diseases as well as their characteristics is not fully elucidated. The basic aim of this research was to determine interleukin-33 serum levels in children with allergic asthma and allergic rhinitis, as well as to examine the relationship between obtained interleukin-33 levels and individual clinical characteristics of these patients. Material and Methods. Serum interleukin- 33 levels were measured in a total of 91 children. The study group included 39 children with both allergic asthma and allergic rhinitis, and also 22 children with allergic asthma without allergic rhinitis. The control group included 30 healthy children. Results. Serum levels of interleukin-33 in children with both allergic asthma and allergic rhinitis were significantly higher compared to those in children with allergic asthma only (?2 = 7.01; p = 0.008; p < 0.01). Both groups of patients had significantly higher interleukin-33 serum levels compared to healthy children (?2 = 7.01; p = 0.008; p < 0.01). The correlation between serum interleukin-33 levels and allergic asthma severity was statistically significant (rs = 0.289; p = 0.024; p < 0.05). Conclusion. Serum levels of interleukin-33 were significantly higher in children with allergic respiratory diseases compared to healthy examinees. Significantly higher levels of serum interleukin-33 levels were found in children with both allergic asthma and allergic rhinitis, compared to children with allergic asthma only. Patients with higher interleukin- 33 serum levels also had a more severe type of allergic asthma.

Download Full-text

Serum immunoglobulin E reactivity to cross-reacting panallergen components in north-eastern Poland patients pollen sensitized

Allergy and Asthma Proceedings ◽

10.2500/aap.2020.41.200002 ◽

2020 ◽

Vol 41 (3) ◽

pp. 183-191

Author(s):

Krzysztof Kowal ◽

Agnieszka Pampuch ◽

Ewa Sacharzewska ◽

Ewa Swiebocka ◽

Zenon Siergiejko ◽

...

Keyword(s):

Allergic Rhinitis ◽

Allergen Immunotherapy ◽

Immunoglobulin E ◽

Pollen Allergy ◽

Serum Ige ◽

Ige Reactivity ◽

Allergen Components ◽

North Eastern ◽

Allergen Sources ◽

Seasonal Pollen

Background: The presence of immunoglobulin E (IgE), which cross-reacts with allergen components, such as profilins, polcalcins, and cross-reacting carbohydrate determinants (CCD), creates a problem when selecting patients for allergen immunotherapy by using conventional methods. The aim of this study was to evaluate the prevalence of sensitization to profilins, polcalcins, and CCDs in patients with seasonal pollen allergic rhinitis. Methods: The study was performed on a group of 112 patients with seasonal pollen allergic rhinitis, ages 14 to 55 years, with sensitization to at least one seasonal allergen (IgE > 0.7 kUA/L). The presence of IgE sensitization to recombinant (r) Bet v 2, rPhl p 12, rBet v 4, rPhl p 7, and CCDs, in addition to rBet v 1, rPhl p 1, rPhl p 5, was evaluated by using a multiparameter immunoblot. Results: Among the studied patients, 64.3, 80.4, and 41.1% were sensitized to birch, timothy grass, and mugwort pollen, respectively. Sensitization to profilins rBet v 2/Phl p 12 was demonstrated in 28.6%, to polcalcins Bet v 4/Phl p 7 in 8.9%, and to CCDs in 25%. In 29.3%, serum IgE reactivity to any of the cross-reactive components could be demonstrated. Serum IgE reactivity to rBet v 2 was always accompanied by IgE reactivity to rPhl p 12, and IgE reactivity to rBet v 4 was always accompanied by IgE reactivity to rPhl p 7. Among the patients with pollinosis co-sensitized to at least two allergen sources according to extract-based diagnosis, possible false-positive results due to sensitization to cross-reactive components were detected in 17.9%. Conclusion: Evaluation of sensitization to cross-reacting components may be useful in evaluation of patients with pollen allergy who are being assessed for allergen immunotherapy to optimize the constitution of their immunotherapy vaccines.

Download Full-text